Please assess the completion status of the following clinical trial:

Trial Title: Pharmacokinetic and Safety Trial to Determine the Appropriate Dose for Pediatric Patients With Multidrug Resistant Tuberculosis

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Confirmed diagnosis of MDR-TB OR~* Presumptive diagnosis of MDR-TB including one of the following:~  * Clinical specimen suggestive of TB~ * Persistent cough lasting \> 2 weeks~ * Fever, weight loss, and failure to thrive~ * Findings on recent chest radiograph (prior to Visit 1) consistent with TB AND~ * Household contact of a person with known MDR-TB or a person who died while appropriately taking drugs for sensitive TB OR~ * On first-line TB treatment but with no clinical improvement~* Negative urine pregnancy test for female patients who have reached menarche~* Written informed consent/assent~Exclusion Criteria:~* Laboratory evidence of active hepatitis B or C~* Children with body weight \< 5.5 kg~* For patients with HIV co-infection, CD4 cell count ≤ 1000/mm3 for children 1-5 years old, and ≤ 1500/mm3 for children less than 1 year old~* History of allergy to metronidazole and any disease or condition in which metronidazole is required~* Use of amiodarone within 12 months or use of other predefined antiarrhythmic medications within 30 days prior to first dose of delamanid~* Serious concomitant conditions~* Preexisting cardiac conditions~* Abnormalities in Screening ECG (including AV block, BBB or hemi-block, QRS prolongation \> 120 msec, or QTcF \> 450 msec in both males and females)~* Concomitant condition such as renal impairment characterized by serum creatinine levels \>1.5 mg/dL, hepatic impairment (ALT or AST \> 3x ULN), or hyperbilirubinemia characterized by total bilirubin \> 2x ULN~* Current diagnosis of severe malnutrition or kwashiorkor~* Positive urine drug screen (Groups 1 and 2 only)~* Rifampicin and/or moxifloxacin within 1 week prior to the first dose of delamanid and/or any prior or concurrent use of bedaquiline~* Lansky Play Performance Score \< 50 (not applicable for children \< 1 year old) or Karnofsky Score \< 50~* Administered an IMP within 1 month prior to Visit 1~* Pregnant, breast-feeding, or planning to conceive or father a child within the timeframe described in the information consent form (Groups 1 and 2 only)

- Gender: ALL
- Minimum Age: None
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Group 1: 12 to 17 years of age (Type: EXPERIMENTAL): Group 1: 100 mg Delamanid BID for 10 days + OBR
- Group 2: 6 to 11 years of age (Type: EXPERIMENTAL): 50 mg Delamanid BID for 10 days + OBR
- Group 3: 3 to 5 years of age (Type: EXPERIMENTAL): 25 mg Pediatric Formulation Delamanid BID for 10 days + OBR
- Group 4: Birth to 2 years of age (Type: EXPERIMENTAL): Delamanid Pediatric Formulation (DPF) for 10 days + OBR. DPF dose based on patient's body weight during baseline visit:~* Patient's \> 10 kg will receive DPF 10 mg BID + OBR~* Patient's \> 8 kg and ≤ 10 kg will receive DPF 5 mg BID + OBR~* Patients ≤ 8 kg will receive DPF 5 mg QD + OBR

Based on this trial design, predict the completion outcome and termination type (if applicable).